Compare PRSO & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRSO | BCAB |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8M | 7.5M |
| IPO Year | 2000 | 2020 |
| Metric | PRSO | BCAB |
|---|---|---|
| Price | $1.39 | $4.51 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 716.4K | 32.3K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.23 | 29.86 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $14,573,000.00 | $300,000.00 |
| Revenue This Year | $18.48 | N/A |
| Revenue Next Year | $53.57 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 5.99 | N/A |
| 52 Week Low | $0.77 | $0.12 |
| 52 Week High | $2.37 | $6.52 |
| Indicator | PRSO | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 71.22 | 56.41 |
| Support Level | $1.38 | $0.36 |
| Resistance Level | $1.63 | $6.33 |
| Average True Range (ATR) | 0.08 | 0.50 |
| MACD | 0.03 | -0.17 |
| Stochastic Oscillator | 69.63 | 28.50 |
Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz, to 300 GHz. Geographically the company generates revenue from the United States, Hong Kong, Taiwan, and the Rest of the World.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.